Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HLA typing 1434-1, 1434-3

ABSTRACT: HLA typing of a family (patient and his father) for donor selection to haploidential transplantation of hematopoetic stem cells(HSC) 1434-1, 1434-3

PROVIDER: PRJEB12062 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1172416_1.fastq.gz	Fastqsanger.gz
	ERR1172416_2.fastq.gz	Fastqsanger.gz
	ERR1172417_1.fastq.gz	Fastqsanger.gz
	ERR1172417_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

HLA typing 1432-1, 1432-3

Project description:HLA typing of a family (patient and his mother) for donor selection to haploidential transplantation of hematopoetic stem cells(HSC) 1432-1, 1432-3

| PRJEB12061 | ENA

HLA typing 1140-1, 1140-2

Project description:HLA typing of a family (patient and his mother) for donor selection to haploidential transplantation of hematopoetic stem cells(HSC) 1140-1, 1140-2

| PRJEB12060 | ENA

Project description:HLA typing of a family (patient, his mother and father) for donor selection to haploidential transplantation hematopoetic stem cells

| PRJEB11416 | ENA

HLA-type

Project description:HLA typing for donor registry

| PRJEB37094 | ENA

HLA-type

Project description:HLA typing for donor registry

| PRJEB37096 | ENA

HLA typing by SMRT DNA sequencing

Project description:HLA typing by SMRT DNA sequencing

| PRJEB21509 | ENA

HLA typing by NGS

Project description:HLA typing of 96 samples in one run of the Illumina MiSeq

| PRJEB7337 | ENA

Oxford Nanopore RNA sequencing for HLA typing

Project description:A targeted RNA-based method for typing of 12 classical HLA genes using Oxford Nanopore sequencing. In the method, were enriched HLA genes from cDNA of 50 individuals using gene-specific reverse primers. The library molecules were then barcoded, pooled into 2 separate gene pools, and sequenced on MinION R9.4 SpotON flow cells.

| EGAS00001004918 | EGA

GENOMICS TO IDENTIFY HLA IDENTICAL RENAL TRANSPLANT TOLERANCE SIGNATURES

Project description:Immunosuppression is needed in HLA identical sibling renal transplantation. We conducted a tolerance trial in this patient cohort using Alemtuzumab induction, donor hematopoietic stem cells, tacrolimus/mycophenolate immunosuppression converted to sirolimus, planning complete drug withdrawal by 24 months post-transplantation. After an additional 12 months with no immunosuppression, normal biopsies and renal function, recipients were considered tolerant. Twenty recipients were enrolled. Of the first 10 (>36 months post-transplantation), 5 had immunosuppression successfully withdrawn for 16-36 months (tolerant), 2 had disease recurrence and 3 had subclinical rejection in protocol biopsies (non-tolerant). Microchimerism disappeared after 1 year, and CD4+CD25highCD127-FOXP3+ T cells and CD19+IgD/M+CD27- B cells increased to 5 years post-transplantation in both groups, whereas immune/inflammatory gene expression pathways in the peripheral blood and urine were differentially downregulated in tolerant compared to non-tolerant recipients. Therefore, in this HLA identical renal transplant tolerance trial, absent chimerism, Treg and Breg immunophenotypes were indistinguishable between tolerant and non-tolerant recipients, but global genomic changes indicating immunomodulation were observed only in tolerant recipients.

2013-04-01 | GSE45593 | GEO

Expression date from endothelial cells stimulated with anti-HLA class I and anti-A antibody

Project description:While donor specific antibody (DSA) against HLA class II could frequently cause chronic antibody-mediated rejection (ABMR) in organ transplantation, anti-A/B antibody would not do so, because blood group ABO-incompatible transplantation has shown favorable graft outcome. Recently, an increasing attention has been paid to the importance of direct allorecognition of CD4 T-cells against HLA-class II expressed on graft endothelial cells. However, the effect of allo-antibody binding on its allorecognition remains unclear. Microarray analysis and molecular profiling demonstrated that CD275 (PD-L1) expression was increased by anti-A/B ligation-mediated ERK inactivation in endothelial cells despite IFNγ stimulation.

2018-09-28 | GSE120545 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data